Bear Mountain Capital, Inc. Phathom Pharmaceuticals, Inc. Transaction History
Bear Mountain Capital, Inc.
- $246 Billion
- Q2 2024
A detailed history of Bear Mountain Capital, Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Bear Mountain Capital, Inc. holds 1,000 shares of PHAT stock, worth $17,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000
Previous 200
400.0%
Holding current value
$17,250
Previous $1.96 Million
494.39%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
124Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$174 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$129 Million27.45% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$60.3 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$54.2 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$50.5 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $676M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...